What is CellChorus?
CellChorus operates at the intersection of biotechnology and artificial intelligence, specializing in dynamic single-cell analysis. Its proprietary Time-lapse Imaging Microscopy in Nanowell Grids (TIMING) platform serves as a cornerstone for modern biological research. By utilizing visual AI to monitor cell behavior in real-time, the company provides granular insights into cellular interactions and performance metrics. This technological framework is essential for clinical trial selection and the broader understanding of complex biological responses, positioning CellChorus as a critical infrastructure provider for pharmaceutical and academic institutions alike. The integration of motion-based analysis with multiomic profiling allows for a comprehensive view of cellular function, setting a new standard for precision in life sciences.
How much funding has CellChorus raised?
CellChorus has raised a total of $2.5M across 1 funding round:
Grant
$2.5M
Grant (2024): $2.5M with participation from National Institutes of Health
Key Investors in CellChorus
National Institutes of Health
The National Institutes of Health is the primary agency of the United States government responsible for biomedical and health-related research, providing critical funding for innovative scientific advancements.
What's next for CellChorus?
With this major strategic investment, CellChorus is well-positioned to scale its operations and expand the reach of its TIMING platform. The company is expected to focus on enhancing its AI-driven analytical capabilities, potentially broadening its application across diverse cell types and therapeutic areas. As the demand for high-resolution, dynamic cellular data grows within the biopharmaceutical sector, CellChorus is likely to prioritize commercial partnerships and the further validation of its platform in clinical settings. This growth trajectory suggests a transition toward broader market adoption, solidifying its status as a leader in the next generation of diagnostic and research tools.
See full CellChorus company page
